Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Laura Kotaniemi-Talonen"'
Autor:
Ivana Kholová, Olga Veijalainen, Laura Kotaniemi-Talonen, Johanna Mäenpää, Paula Kujala, Saara Kares, Risto Vuento, Tiina Luukkaala
Publikováno v:
Acta obstetricia et gynecologica ScandinavicaREFERENCES. 100(3)
Introduction Since 2012, cervical cancer screening has been conducted with a primary high-risk human papilloma virus (hrHPV) test and conventional cytology triage in the city of Tampere, Finland. The women who were screened with the hrHPV test in 201
Autor:
Pekka Nieminen, J. Melkko, Johanna Arola, Stefan Lönnberg, Jussi Tarkkanen, T. Pietiläinen, Martine Vornanen, Tapio Luostarinen, Ahti Anttila, Laura Kotaniemi-Talonen, H. Kujari, G. Granroth
Publikováno v:
Cytopathology. 23:172-180
S. Lonnberg, P. Nieminen, L. Kotaniemi-Talonen, H. Kujari, J. Melkko, G. Granroth, M. Vornanen, T. Pietilainen, J. Arola, J. Tarkkanen, T. Luostarinen and A. Anttila Large performance variation does not affect outcome in the Finnish cervical cancer s
Autor:
Jukka Melkko, Anna Sankila, Harry Kujari, Martine Vornanen, Tapio Luostarinen, Stefan Lönnberg, Ahti Anttila, Laura Kotaniemi-Talonen, Gustav Granroth, Johanna Arola, Pekka Nieminen, Timo Pietiläinen
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 19:381-387
Background: We assessed the performance and validity of cytology in the Finnish screening program by considering high-grade neoplasia and cervical cancer (CIN3+) rates as detected in the program and by reevaluating cases observed after a negative scr
Autor:
Pekka Nieminen, Jussi Tarkkanen, Laura Kotaniemi-Talonen, Nea Malila, Maarit K. Leinonen, Ahti Anttila, Pekka Laurila
Publikováno v:
JNCI: Journal of the National Cancer Institute. 101:1612-1623
CIN 2, and CIN 3+ for HPV DNA screening with cytology triage vs conventional screening were 1.44 (95% CI = 0.99 to 2.10), 1.39 (95% CI = 1.03 to 1.88), and 1.22 (95% CI = 0.78 to 1.92), respectively. The specificity of the HPV DNA test with cytology
Autor:
Ahti Anttila, Terttu Toivonen, Jussi Tarkkanen, Jorma Ikkala, Jorma Martikainen, Matti Hakama, Laura Kotaniemi-Talonen, Pekka Nieminen
Publikováno v:
Journal of Medical Screening. 14:23-28
Objectives: New cervical screening methods have been developed. They seem to become accepted in routine use without randomized trials, within existing screening programmes. Our aim was to evaluate, in a randomized setting, the performance of automati
Publikováno v:
British Journal of Cancer
The role of high-risk human papillomavirus (hrHPV) testing in primary cervical screening has not been established. We generated a randomised evaluation design ultimately to clarify whether primary hrHPV testing implemented into routine screening can
Autor:
Maarit K. Leinonen, Matti Hakama, Laura Kotaniemi-Talonen, Pirkka-Pekka Laurila, Jussi Tarkkanen, Nea Malila
Publikováno v:
International journal of cancer. 132(9)
We compared test sensitivity (in terms of prevented cancers) and overdiagnosis (in terms of non-progressive pre-invasive lesions) between the human papillomavirus test (HPV test, Hybrid Capture 2) and the traditional Pap test in routine screening for
Publikováno v:
Acta oncologica (Stockholm, Sweden). 50(1)
Based on a five-year follow-up of 130 692 women who participated in the five-yearly organised screening in Finland in 1995, we estimated the risk for incident invasive cervical cancer and severe precancerous lesion for groups of women with different
Autor:
Matti Hakama, Pekka Nieminen, Nea Malila, Maarit K. Leinonen, Ahti Anttila, Pekka Laurila, Laura Kotaniemi-Talonen, Jussi Tarkkanen
Publikováno v:
The BMJ
Objective To assess the performance and impact of primary human papillomavirus (HPV) DNA screening with cytology triage compared with conventional cytology on cervical cancer and severe pre-cancerous lesions. Design Randomised trial. Setting Populati
Autor:
Laura Kotaniemi-Talonen, Pekka Nieminen, Ahti Anttila, Nea Malila, Matti Hakama, Arun Pokhrel
Publikováno v:
International journal of cancer. 128(5)
The purpose was to evaluate alternative cytological screening methods in population-based screening for cervical cancer up to cancer incidence and mortality outcome. Automation-assisted screening was compared to conventional cytological screening in